We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Evolent Health (EVH) Completes Acquisition of Valence Health
Read MoreHide Full Article
Evolent Health Inc. (EVH - Free Report) announced that it has completed the acquisition of Valence Health. The deal was announced in Jul 2016. Per the agreement, the company paid $219.4 million for the acquisition. The price is based on the closing price of Evolent's Class A common stock as on Oct 3, 2016, and consists of 7.05 million shares of Evolent Class A common stock and $50.3 million in cash.
As a standalone business, Valence is estimated to generate revenues of $80–$85 million (nearly 90% recurring) in calendar year 2016. Approximately 25% of revenues should come from population health and advisory services, while Medicaid and pediatric services are likely to generate the rest.
Valence has a strong clientele that includes the likes of The University of Chicago, Cincinnati Children’s, NorthShore among others. Notably, the deal adds a significant scale to Evolent’s business, as the combined entity serves 23 long-term operating partners and more than 1.8 million lives in 30 plus states.
Per Evolent, the acquisition will accelerate its break-even EBITDA target in 2017 by one or two quarters. Apart from financial benefits, the acquisition strengthens Evolent’s inherent capabilities and expands its growth prospect. Management noted that Valence’s expertise in Medicaid and pediatric value-based care administration will fill up important gaps in Evolent’s business model.
Evolent also noted that as many as 90 contracts that can bring long-term opportunities are in strategic or initial phases. Per management, the deal will help Evolent to address the needs of the fast growing value-based care market, which is projected to grow more than $45 billion by 2020.
GW Pharmaceuticals has a solid year-to-date return of 91%, way better than the S&P 500’s 5.7% over the same time frame. Notably, the company posted a positive earnings surprise in the last four quarters, the average being 41.6%.
Lantheus Holdings posted a stupendous year-to-date return of 143.4%. Notably, the company expects earnings growth rate of 12.5% over the next 3 to 5 years.
Quidel Corp. has a positive year-to-date return of 2.9%. The stock has a healthy expected earnings growth rate of 20%.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Evolent Health (EVH) Completes Acquisition of Valence Health
Evolent Health Inc. (EVH - Free Report) announced that it has completed the acquisition of Valence Health. The deal was announced in Jul 2016. Per the agreement, the company paid $219.4 million for the acquisition. The price is based on the closing price of Evolent's Class A common stock as on Oct 3, 2016, and consists of 7.05 million shares of Evolent Class A common stock and $50.3 million in cash.
As a standalone business, Valence is estimated to generate revenues of $80–$85 million (nearly 90% recurring) in calendar year 2016. Approximately 25% of revenues should come from population health and advisory services, while Medicaid and pediatric services are likely to generate the rest.
Valence has a strong clientele that includes the likes of The University of Chicago, Cincinnati Children’s, NorthShore among others. Notably, the deal adds a significant scale to Evolent’s business, as the combined entity serves 23 long-term operating partners and more than 1.8 million lives in 30 plus states.
Per Evolent, the acquisition will accelerate its break-even EBITDA target in 2017 by one or two quarters. Apart from financial benefits, the acquisition strengthens Evolent’s inherent capabilities and expands its growth prospect. Management noted that Valence’s expertise in Medicaid and pediatric value-based care administration will fill up important gaps in Evolent’s business model.
EVOLENT HEALTH Price
EVOLENT HEALTH Price | EVOLENT HEALTH Quote
Evolent also noted that as many as 90 contracts that can bring long-term opportunities are in strategic or initial phases. Per management, the deal will help Evolent to address the needs of the fast growing value-based care market, which is projected to grow more than $45 billion by 2020.
Zacks Rank & Key Picks
Better-ranked stocks in the broader medical sector are GW Pharmaceuticals Plc. , Lantheus Holdings Inc. (LNTH - Free Report) and Quidel Corp. (QDEL - Free Report) . Notably, all three stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
GW Pharmaceuticals has a solid year-to-date return of 91%, way better than the S&P 500’s 5.7% over the same time frame. Notably, the company posted a positive earnings surprise in the last four quarters, the average being 41.6%.
Lantheus Holdings posted a stupendous year-to-date return of 143.4%. Notably, the company expects earnings growth rate of 12.5% over the next 3 to 5 years.
Quidel Corp. has a positive year-to-date return of 2.9%. The stock has a healthy expected earnings growth rate of 20%.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>